Marcell I. Lederer

Kurt Mothes Str. 3A
Halle, NI 06120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer.

Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer.

Journal: Signal transduction and targeted therapy
Published: May 30, 2025

The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer.

The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer.

Journal: NAR cancer
Published: October 16, 2024

RAVER1 hinders lethal EMT and modulates miR/RISC activity by the control of alternative splicing.

RAVER1 hinders lethal EMT and modulates miR/RISC activity by the control of alternative splicing.

Journal: Nucleic acids research
Published: June 15, 2023

IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.

IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.

Journal: Molecular cancer
Published: March 23, 2023

Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients.

Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients.

Journal: PloS one
Published: August 26, 2022

Musashi-1-A Stemness RBP for Cancer Therapy?

Musashi-1-A Stemness RBP for Cancer Therapy?

Journal: Biology
Published: April 11, 2021

Oncogenic Potential of the Dual-Function Protein MEX3A.

Oncogenic Potential of the Dual-Function Protein MEX3A.

Journal: Biology
Published: April 08, 2021

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.

Journal: Frontiers in oncology
Published: December 30, 2020

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer.

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer.

Journal: RNA biology
Published: September 03, 2020

Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice.

Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice.

Journal: NAR cancer
Published: May 04, 2020

The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer.

The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer.

Journal: Nucleic acids research
Published: April 16, 2020

IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner.

IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner.

Journal: Nucleic acids research
Published: June 29, 2018
Showing 1-12 of 22

Last Updated: 09/26/2026